{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:conclusion:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Adding SGLT-2i to ARNI/ACEI + BB + MRA is beneficial for reversing cardiac remodeling."}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The new quadruple drug \"ARNI + BB + MRA + SGLT-2i\" is superior to the golden triangle \"ACEI + BB + MRA\" in improving LVEF."}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor neprilysin inhibitors (ARNIs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) are the cornerstones in treating heart failure with reduced ejection fraction (HFrEF)."}
{"doc_id": "med:pmid:38811344", "sentence_id": "med:pmid:38811344:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI + BB + MRA + SGLT-2i (5.83%, 95% CI: 0.53% to 11.14%) and ARNI + BB + MRA (3.83%, 95% CI: 0.72% to 6.90%) were superior to the traditional golden triangle ACEI + BB + MRA in improving LVEF."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence of hypotension-related AEs was higher in the sacubitril/valsartan versus enalapril group but did not affect risk of cardiovascular death or HF hospitalization, which was similar between treatment groups."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARALLEL-HF trial showed that treatment with sacubitril/valsartan resulted in more symptomatic hypotension versus enalapril in Japanese patients with heart failure (HF) and reduced ejection fraction, similar to PARADIGM-HF."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post-hoc analysis characterized hypotension-related adverse events (AEs) and their effects on efficacy using data from PARALLEL-HF, in which patients received sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of 223 patients, 28.2 % experienced hypotension-related AEs and incidence was higher with sacubitril/valsartan versus enalapril (hazard ratio, 2.2; 95 % CI, 1.3-3.8; p = 0.0027)."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, reduction in mean systolic blood pressure from baseline to study end did not significantly differ (sacubitril/valsartan: -2.2 mmHg vs enalapril: -1.3 mmHg; p = 0.6895)."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Hypotension-related AEs leading to treatment discontinuation were not significantly different for sacubitril/valsartan versus enalapril (3.4 % vs 6.9 %, p = 0.5957)."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reduction in risk of cardiovascular death or HF hospitalization was similar with sacubitril/valsartan versus enalapril in patients with or without hypotension-related AEs."}
{"doc_id": "med:pmid:39284545", "sentence_id": "med:pmid:39284545:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study."}
{"doc_id": "med:pmid:39318024", "sentence_id": "med:pmid:39318024:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor-neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (48.1%)."}
{"doc_id": "med:pmid:39318024", "sentence_id": "med:pmid:39318024:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%."}
{"doc_id": "med:pmid:39327768", "sentence_id": "med:pmid:39327768:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At discharge, the proportions of patients on beta-blockers, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor/neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs) were 78% (n = 144), 58% (n = 107) and 55% (n = 101), respectively."}
{"doc_id": "med:pmid:39387766", "sentence_id": "med:pmid:39387766:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255; Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)."}
{"doc_id": "med:pmid:39387766", "sentence_id": "med:pmid:39387766:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) were global, randomized clinical trials testing sacubitril/valsartan against a renin-angiotensin system inhibitor (RASi) (enalapril or valsartan, respectively) in patients with HF and left ventricular ejection fraction ≤40% (PARADIGM-HF) or left ventricular ejection fraction ≥45% (PARAGON-HF)."}
{"doc_id": "med:pmid:39412629", "sentence_id": "med:pmid:39412629:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure."}
{"doc_id": "med:pmid:39439294", "sentence_id": "med:pmid:39439294:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "PARADIGM-HF and PARAGON-HF were randomized trials testing sacubitril/valsartan versus enalapril or valsartan, respectively, in patients with HF and LVEF ≤40% (PARADIGM-HF) or LVEF ≥45% (PARAGON-HF)."}
{"doc_id": "med:pmid:39455534", "sentence_id": "med:pmid:39455534:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor/neprilysin inhibitors (ARNIs) are the first choice for patients with HF and reduced ejection fraction, with ACEis being the second choice in this group."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi)."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This was a retrospective cohort study including patients with HFrEF who were transitioned from ACEi to ARNI during their hospital stay between March 1, 2016 and December 31, 2022."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:methods:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Conclusion and relevance</h4> This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF."}
{"doc_id": "med:pmid:39497472", "sentence_id": "med:pmid:39497472:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI."}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan may be more effective than enalapril in reducing the risk of death in patients not treated with a beta-blocker compared to those treated with a beta-blocker, but is effective regardless of beta-blocker use."}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Safety outcomes related to sacubitril/valsartan versus enalapril did not differ according to background beta-blocker use."}
{"doc_id": "med:pmid:39563094", "sentence_id": "med:pmid:39563094:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effect of sacubitril/valsartan compared to enalapril on outcomes according to background beta-blocker treatment in the 8399 patients with heart failure with reduced ejection fraction enrolled in PARADIGM-HF."}
{"doc_id": "med:pmid:39571389", "sentence_id": "med:pmid:39571389:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Key predictors included the E/e' ratio, NYHA classification, LVEF, age, BNP levels, MLR, history of atrial fibrillation (AF), use of ACEI/ARB/ARNI, and history of myocardial infarction (MI)."}
{"doc_id": "med:pmid:39602121", "sentence_id": "med:pmid:39602121:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Not filling a cardiovascular medication after hospitalization was associated with not filling that medication at the time of discharge (adjusted risk ratio, 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for β-blockers; 0.20 [0.19-0.20] for P2Y12Is; 0.31 [0.31-0.32] for statins or PCSK9Is; and 0.27 [0.26-0.28] for SGLT2Is or GLP-1RAs)."}
{"doc_id": "med:pmid:39602121", "sentence_id": "med:pmid:39602121:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Main outcome and measures</h4> Medicare Part D prescription fill records were examined for the following agents: (1) angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); (2) β-blockers; (3) platelet adenosine diphosphate receptor inhibitors (P2Y12Is); (4) statins or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is); and (5) glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2Is)."}
{"doc_id": "med:pmid:39620289", "sentence_id": "med:pmid:39620289:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i)."}
{"doc_id": "med:pmid:39620289", "sentence_id": "med:pmid:39620289:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While 52.6% of physicians considered angiotensin receptor-neprilysin inhibitor (ARNi) treatment the most effective medication for HF, 62.7% would initiate HF treatment with an angiotensin-converting enzyme inhibitor (ACEi) instead of ARNi due to reimbursement and cost issues."}
{"doc_id": "med:pmid:39622578", "sentence_id": "med:pmid:39622578:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "HFrEF patients with symptomatic LVEF≤35% despite ACE inhibitor/beta blocker/mineralocorticoid receptor antagonist therapy, and qualified for sacubitril/valsartan switchover were recruited to this single centre prospective study."}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), and angiotensin II receptor blocker (ARB) prescription at discharge were evaluated across 3 time periods."}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Main outcomes and measures</h4> Rates of ARNI, ACEI, and ARB prescription at discharge were evaluated across 3 time periods as follows: (1) period 1 included the US Food and Drug Administration (FDA) approval of sacubitril-valsartan to the day before the PIONEER-HF (Comparison of Sacubitril-Valsartan vs Enalapril on Effect on N-Terminal Pro-Brain Natriuretic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication (July 7, 2015-November 10, 2018); (2) period 2 included the day of the PIONEER-HF trial publication to the day before publication of the 2021 Update to the 2017 Consensus for Optimization of Heart Failure Treatment (November 11, 2018-January 10, 2021); and (3) period 3 included the day of the 2021 update publication to the last available data at the time of analysis (January 11, 2021-December 31, 2022)."}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI or ARB prescription at discharge fell from 88.3% (2612 of 2957) to 45.9% (2033 of 4434) over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to 84.7% (3990 of 4711)."}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In adjusted logistic regression models, compared with period 1, patients discharged during period 2 and period 3 were found to have a 3.81-fold (95% CI, 3.65-3.98) and 9.15-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45-0.48) and 0.25 (95% CI, 0.24-0.26) decreased odds of ACEI or ARB prescription at discharge."}
{"doc_id": "med:pmid:39661383", "sentence_id": "med:pmid:39661383:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Conclusions and relevance</h4> Results of this cross-sectional study reveal that in the 7 years after FDA drug approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of ACEI or ARB prescription decreased."}
{"doc_id": "med:pmid:39687932", "sentence_id": "med:pmid:39687932:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors."}
{"doc_id": "med:pmid:39719408", "sentence_id": "med:pmid:39719408:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Individual patient data from the PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF) and PARADIGM-HF (Prospective Comparison of ARNI With ACEI [Angiotensin-Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in HF) trials were used to examine patient characteristics and outcomes according to quartiles of PNI."}
{"doc_id": "med:pmid:39720381", "sentence_id": "med:pmid:39720381:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Combining beta-blockers and ACE inhibitors, or integrating them with newer agents such as angiotensin receptor-neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists (MRAs), provides an additive benefit, improving long-term survival and reducing heart failure-related hospitalizations."}
{"doc_id": "med:pmid:39792134", "sentence_id": "med:pmid:39792134:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed."}
{"doc_id": "med:pmid:39792134", "sentence_id": "med:pmid:39792134:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Previous studies have reported that angiotensin receptor-neprilysin inhibitors (ARNI) are superior to angiotensin-converting enzyme inhibitors (ACEI) in treating heart failure with reduced ejection fraction (HFrEF)."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A higher KCCQ overall score was observed in the ARNI group in contrast to the ACEI group (<i>p</i>=0.01)."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI demonstrated superior results in improving the ejection fraction as compared with ACEI (<i>p</i>=0.001)."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In conclusion, ARNI was more efficacious than ACEI in improving the quality of life and left ventricular ejection fraction of patients with HFrEF."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The aim of this study was to compare the efficacies of ARNI and ACEI on patients with HFrEF in Indonesia."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Both ACEI and ARNI each consisted of 40 subjects receiving standard treatment for heart failure."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Paired <i>t</i>-test was used to compare the outcomes of ACEI and ARNI."}
{"doc_id": "med:pmid:39816068", "sentence_id": "med:pmid:39816068:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results revealed that KKCQ score and LVEF were improved in both ARNI and ACEI groups (each with <i>p</i><0.001)."}
{"doc_id": "med:pmid:39829077", "sentence_id": "med:pmid:39829077:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "GDMT was defined by five medication classes-angiotensin-converting enzyme (ACE) inhibitors (ACEis)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is) and vasodilators (Black patients only)."}
{"doc_id": "med:pmid:39829077", "sentence_id": "med:pmid:39829077:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among the 93.8% on some form of GDMT, 82.8%, 81.4%, 23.5%, 3.6% and 13.4% were on ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators (Black patients only), respectively."}
{"doc_id": "med:pmid:39829077", "sentence_id": "med:pmid:39829077:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among treated patients, 45.8%, 21.4%, 77.6%, 100% and 14.7% were treated at ≥80% of the target dose for ACEis/ARBs/ARNis, BBs, MRAs, SGLT2is and vasodilators, respectively."}
{"doc_id": "med:pmid:39864551", "sentence_id": "med:pmid:39864551:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan is a promising alternative to ARB or ACEi in managing RH, offering superior blood pressure reductions and potential benefits in reversing cardiac remodeling, while maintaining a favorable safety profile with minimal risk of serious adverse events."}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among patients with de novo HFrEF, sacubitril/valsartan (compared with that of ACEi/ARB) was associated with fewer all-cause, CV and HF hospitalizations."}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States."}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020."}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi/ARB were analysed."}
{"doc_id": "med:pmid:39888167", "sentence_id": "med:pmid:39888167:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan cohort when compared with the ACEi/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75-0.89, P < 0.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73-0.87, P < 0.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78-0.95, P = 0.002)."}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi/ARB/ARNi."}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among the 999 included patients, β-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin-neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%."}
{"doc_id": "med:pmid:39922597", "sentence_id": "med:pmid:39922597:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariate analysis, the use of ACEi/ARB/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p<0.01)."}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increased age was associated with less likelihood of the prescription of ACEIs/ARBs/ARNIs and mineralocorticoid receptor antagonists at any dose and ≥50% target dose."}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Better renal function was a predictor for ACEIs/ARBs/ARNIs at any dose and ≥50% target dose."}
{"doc_id": "med:pmid:39939202", "sentence_id": "med:pmid:39939202:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The prescription of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs) and mineralocorticoid receptor antagonists at any dose (52% vs 80%; p<0.01, 25% vs 52%; p<0.01, respectively) were lower in non-cardiology than in cardiology wards, but there was no difference between wards for beta blockers."}
{"doc_id": "med:pmid:39970741", "sentence_id": "med:pmid:39970741:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan or enalapril prevented deterioration of myocardial function at 6 months in patients with hematologic malignancies treated with BMT."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The authors investigated whether early initiation of sacubitril/valsartan or enalapril could be helpful to prevent CTRCD in patients undergoing BMT."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:methods:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls)."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients treated with sacubitril/valsartan or enalapril for 6 months did not show a deterioration of LV GLS or LVEF (P > 0.05)."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The percent improvement of GWW and GWE was greater in the sacubitril/valsartan compared to enalapril or control group (P = 0.044 and P = 0.011, respectively) at 6 months."}
{"doc_id": "med:pmid:39983618", "sentence_id": "med:pmid:39983618:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Effect of Sacubitril/Valsartan or Enalapril on Left Ventricular Function in Patients With Hematologic Malignancies Treated With Bone Marrow Transplantation: A Randomized Controlled Trial."}
{"doc_id": "med:pmid:40063170", "sentence_id": "med:pmid:40063170:sec:results:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The prescription rates for key medications were as follows: β-blockers 76.4%, ACE inhibitors/ARBs 71.6%, MRA 63.3%, SGLT2I 33.5%, and ARNI 0%."}
{"doc_id": "med:pmid:40063170", "sentence_id": "med:pmid:40063170:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Medications were classified according to the four-pillar therapy recommended by the AHA, including β-blockers, ARNI, ACE inhibitors/ARBs, SGLT2, and MRAs."}
{"doc_id": "med:pmid:40091512", "sentence_id": "med:pmid:40091512:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The GDMT score (0-8) factored in doses of beta-blocker (BB), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), angiotensin receptor-neprilysin inhibitor (ARNI), isosorbide dinitrate/hydralazine (ISDN/HYD)."}
{"doc_id": "med:pmid:40091512", "sentence_id": "med:pmid:40091512:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prescription rates were 50% for BB, 74.1% for ACEi/ARB/ARNI, 14.8% for SGLT2i, 47% for MRA, and 19.6% for ISDN/HYD."}
{"doc_id": "med:pmid:40101251", "sentence_id": "med:pmid:40101251:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of these, 95% reached titration to either guideline-recommended target doses or maximum tolerated doses for both angiotensin-converting enzyme inhibitor/angiotensin receptor blockers/angiotensin and angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and beta-blockers combined."}
{"doc_id": "med:pmid:40101251", "sentence_id": "med:pmid:40101251:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The mean number of days to achieve titration ranged from 20.2 days for mineralocorticoid receptor antagonist drugs, between 27.5 to 32.3 days for ACEI/ARB/ARNI drugs and 41.0 days for beta-blockers; 70 (79%) patients completed the satisfaction survey at least once, with more than 98% of survey questions receiving a positive response."}
{"doc_id": "med:pmid:40105368", "sentence_id": "med:pmid:40105368:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses."}
{"doc_id": "med:pmid:40115097", "sentence_id": "med:pmid:40115097:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Statistical comparison between two groups was performed, which focused on indicators of standardized management [proportion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography performed in the diagnosis of HF, application ratio of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), β-blockers in heart failure with reduced ejection fraction (HFrEF) patients, 1 week, 1 month, 3 months and 1 year follow-up rate] and clinical prognosis indicators (NT-proBNP level, 6-minute walking distance test, heart function grading, shorter average duration in hospital) at discharge, review of relevant indicators after 1 year, readmission rate and incidence of main adverse cardiovascular and cerebrovascular events (MACCEs) in 1 year."}
{"doc_id": "med:pmid:40115097", "sentence_id": "med:pmid:40115097:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared to the control group, the proportion of patients using NT-proBNP (94.7% <i>vs.</i> 87.3%, P=0.03), echocardiography (88.7% <i>vs.</i> 78.7%, P=0.02), the ratio of patients using ACEI/ARB/ARNI (87.0% <i>vs.</i> 72.2%, P=0.03) and β-blocker (82.7% <i>vs.</i> 66.7%, P=0.03) before discharge, and the follow-up rate of each period after discharge (1 week, 90.7% <i>vs.</i> 80.0%, P=0.01; 1 month, 84.7% <i>vs.</i> 72.0%, P=0.01; 3 months, 76.7% <i>vs.</i> 64.0%, P=0.02; 1 year, 88.0% <i>vs.</i> 79.3%, P=0.04) was higher in the center group."}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ACEI/ARB, sacubitril/valsartan, and trimetazidine might improve CMD in patients with DbCM."}
{"doc_id": "med:pmid:40188960", "sentence_id": "med:pmid:40188960:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients with elevated NT-pro-BNP had high AMR, and those grouped by medication indicated that ACEI/ARB, sacubitril/valsartan, and trimetazidine might lower AMR in patients with elevated NT-pro-BNP."}
{"doc_id": "med:pmid:40232857", "sentence_id": "med:pmid:40232857:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission."}
{"doc_id": "med:pmid:40255655", "sentence_id": "med:pmid:40255655:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age."}
{"doc_id": "med:pmid:40255655", "sentence_id": "med:pmid:40255655:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk."}
{"doc_id": "med:pmid:40261428", "sentence_id": "med:pmid:40261428:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively."}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In PARADIGM-HF, sacubitril/valsartan, compared with enalapril, reduced the risk of HF hospitalizations, death from cardiovascular causes, and death from any cause similarly in women and men with HF with reduced ejection fraction."}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sex-specific efficacy and safety of sacubitril/valsartan in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) remain unreported."}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post hoc analysis of PARADIGM-HF examined sex-based outcomes in patients with HF and reduced ejection fraction randomized to sacubitril/valsartan or enalapril."}
{"doc_id": "med:pmid:40265590", "sentence_id": "med:pmid:40265590:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with enalapril, sacubitril/valsartan reduced the risk of the primary end point to a similar extent in both sexes: hazard ratios, 0.76 (95% CI, 0.62-0.94) in women and 0.80 (95% CI, 0.73-0.89) in men (<i>P</i>-interaction=0.62)."}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In HF patients with AKD, ARNi was associated with reduced all-cause mortality, MAKE, and readmission risks compared to ACEi, particularly with concurrent mineralocorticoids, diuretics, or beta-blockers."}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study investigated the outcomes of ARNi compared to angiotensin-converting enzyme inhibitors (ACEi) in HF patients with AKD."}
{"doc_id": "med:pmid:40266448", "sentence_id": "med:pmid:40266448:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Propensity score matching (1:1) was applied to balance ARNi and ACEi groups."}
{"doc_id": "med:pmid:40268473", "sentence_id": "med:pmid:40268473:sec:results:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sixty-four HF outpatients with LVEF <50% were randomized to ARNI (switching from an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker [ACEi/ARB] to ARNI) or control (continuing with ACEi/ARB)."}
{"doc_id": "med:pmid:40283370", "sentence_id": "med:pmid:40283370:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (S/V) has been shown to reduce heart failure (HF) hospitalizations and mortality when compared to conventionally administered HF medications (i.e. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs))."}
{"doc_id": "med:pmid:40295134", "sentence_id": "med:pmid:40295134:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the ARNI group, if a patient was on an ACE inhibitor or angiotensin II receptor blocker before TAVI, it will be switched to ARNI 100 mg/day (50 mg two times per day) on the first postoperative day."}
{"doc_id": "med:pmid:40302030", "sentence_id": "med:pmid:40302030:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy (angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB]/angiotensin receptor-neprilysin inhibitor [ARNI]; beta-blocker (BB); mineralocorticoid receptor antagonist [MRA]; sodium-glucose co-transporter 2 inhibitor [SGLT2i]) in patients with heart failure and reduced ejection fraction (HFrEF)."}
{"doc_id": "med:pmid:40302030", "sentence_id": "med:pmid:40302030:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "HF drug prescription rates were as follows: ACEI 46.3%, ARB 31.8%, ARNI 12.1%, BB 80.9%, MRA 35.6%, SGLT2i 7.3%."}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At the cost-effectiveness threshold of RM55 426 per QALY, ARNI is cost-effective compared with ACEI for the heart failure with reduced ejection fraction population."}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study compared the costs and effectiveness of angiotensin receptor neprilysin inhibitor (ARNI) with angiotensin-converting enzyme inhibitor (ACEI) for the heart failure with reduced ejection fraction population from the Malaysian Ministry of Health's perspective."}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A 3-state Markov model, with a monthly cycle, was constructed to estimate the lifetime healthcare costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) of ARNI and ACEI."}
{"doc_id": "med:pmid:40319618", "sentence_id": "med:pmid:40319618:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite ARNI being more expensive compared with ACEI, it gained more QALYs, resulting in an ICER of RM46 498 per QALY."}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:conclusion:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We found high frequencies of prescription of GDMT for HFrEF, considering the therapeutic goals recommended by cardiology guidelines, but, prescription of target doses were low in ACEi, ARB or ARNi and beta-blockers."}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Only 21,2% were prescribed GDMT target doses of enalapril, losartan or ARNi and 52,3% of beta-blockers."}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "93.1% were prescribed ACEi, ARB or ARNi, 95.8% betablockers, 69.2% spironolactone and 8% the combination hydralazine/isosorbide-dinitrate."}
{"doc_id": "med:pmid:40332281", "sentence_id": "med:pmid:40332281:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "71,7% were using enalapril, losartan or ARNi above 50% of GDMT target doses; 81,2% were using beta-blockers and 100% were using spironolactone."}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:discussion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Reductions were comparable between sacubitril/valsartan and enalapril, with a numerically greater reduction observed in adult patients versus children."}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:discussion:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "of 361 paediatric patients (sacubitril/valsartan, n = 179; enalapril, n = 182) demonstrated overall higher baseline NT-proBNP levels in younger AGs."}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PANORAMA-HF trial demonstrated significant N-terminal pro-B-type natriuretic peptide (NT-proBNP) reductions in paediatric patients with left ventricular systolic dysfunction with sacubitril/valsartan or enalapril treatment over 52 weeks."}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This post hoc analysis aims to correlate changes in NT-proBNP levels with clinical outcomes in PANORAMA-HF patients receiving either sacubitril/valsartan or enalapril."}
{"doc_id": "med:pmid:40353367", "sentence_id": "med:pmid:40353367:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Associations between baseline NT-proBNP levels, changes post-baseline and the risk of HF clinical events in paediatric patients on sacubitril/valsartan or enalapril were assessed."}
{"doc_id": "med:pmid:40385266", "sentence_id": "med:pmid:40385266:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The combination therapy of angiotensin-converting enzyme inhibitors (ACEi) or alternatively angiotensin receptor-neprilysin inhibitors (ARNis), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and recently sodium-glucose co-transporter 2 inhibitors (SGLT2is) has been hailed as a breakthrough in heart failure treatment for patients with structurally normal hearts, with international guidelines recommending these as first-line therapies (\"fantastic four\")."}
{"doc_id": "med:pmid:40389107", "sentence_id": "med:pmid:40389107:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study investigated the effect of uptitration of sacubitril/valsartan (Sac/Val) compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level within current guideline-directed medical therapy in acute heart failure (AHF)."}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients diagnosed with HF and prescribed either sacubitril/valsartan or angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) within 90 days of their first HF diagnosis between October 2017 and December 2020 were included."}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 7085 sacubitril/valsartan users and 359 153 ACEI/ARB users, 6930 sacubitril/valsartan users [mean (SD) age, 61.7 (14.6) years; 70.9% male] were matched on propensity score to 27 720 ACEI/ARB users [mean (SD) age, 61.7 (15.8) years; 71.1% male]."}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "During a mean follow-up of 2.2 and 2.3 years, dementia occurred in 200 (2.9%) sacubitril/valsartan users and 980 (3.5%) ACEI/ARB users, respectively."}
{"doc_id": "med:pmid:40397431", "sentence_id": "med:pmid:40397431:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan showed a 16% lower risk of dementia compared with ACEI/ARB (HR 0.84; 95% CI 0.72-0.98)."}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs."}
{"doc_id": "med:pmid:40418165", "sentence_id": "med:pmid:40418165:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI."}
{"doc_id": "med:pmid:40448468", "sentence_id": "med:pmid:40448468:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The purpose of this study was to compare the efficacy and safety of triple GDMT with a sodium-glucose cotransporter inhibitor (SGLTi) vs mineralocorticoid receptor antagonist (MRA) added to beta blocker and angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNi)."}
{"doc_id": "med:pmid:40448468", "sentence_id": "med:pmid:40448468:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients who received triple GDMT therapy with a SGLTi or MRA added to beta blocker and ACEi/ARB/ARNi therapy at discharge were compared."}
{"doc_id": "med:pmid:40450497", "sentence_id": "med:pmid:40450497:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We systematically evaluated sacubitril/valsartan (S/V) effects on the renal outcomes of patients with acute or chronic heart failure (HF) receiving angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB)."}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor-neprilysin inhibitor (ARNI) has superior beneficial effects on mortality and quality of life compared to angiotensin-converting enzyme inhibitor (ACEI)."}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:introduction:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study was conducted to evaluate the possible impact of ARNI therapy compared to ACEI on cardiac remodeling using echocardiographic parameters, including global longitudinal strain (GLS) in heart failure with reduced left ventricular ejection fraction (HFrEF) patients."}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study included two groups: the ARNI group included forty patients prescribed ARNI, and the ACEI group included forty patients prescribed ACEI."}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "There was a significant improvement in the ARNI group regarding LVEF (<i>P</i> = 0.011), 2D GLS (<i>P</i> < 0.001), and 3D GLS compared to the ACEI group, but no significant change in the LV mass index."}
{"doc_id": "med:pmid:40463763", "sentence_id": "med:pmid:40463763:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After a 6-month follow-up period, there was a significant reduction in LV-indexed volumes in the ARNI group (<i>P</i> < 0.001) and indexed left atrial volumes (<i>P</i> = 0.013) compared to the ACEI group."}
{"doc_id": "med:pmid:40470816", "sentence_id": "med:pmid:40470816:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At baseline, beta-blockers, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), mineralocorticoid receptor antagonist (MRA) and loop diuretic use was 84% versus 86%, 89% versus 88%, 57% versus 46% and 62% versus 59% in patients receiving versus not receiving CRT, respectively."}
{"doc_id": "med:pmid:40470816", "sentence_id": "med:pmid:40470816:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A significant association between CRT and the likelihood of ACEi/ARB/ARNi and MRA optimization (OR 1.22, 95% CI 1.04-1.44, and OR 1.25, 95% CI 1.05-1.50, respectively) was observed in the per-protocol analysis."}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as a promising alternative to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in HF management."}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "We conducted a systematic review and meta-analysis of published studies assessing the use of ARNIs in ACHD patients with HF, comparing them to ACEIs/ARBs."}
{"doc_id": "med:pmid:40486108", "sentence_id": "med:pmid:40486108:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Substituting ACEIs/ARBs with ARNIs significantly improved the NYHA functional class (log odds ratio [log OR] 0.67, 95% CI 0.15-1.19; <i>p</i> = 0.01)."}
{"doc_id": "med:pmid:40540017", "sentence_id": "med:pmid:40540017:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "CDMT was defined as concurrent use of angiotensin-converting-enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB) /angiotensin receptor-neprilysin inhibitor (ARNI) plus beta-blocker (BB) plus mineralocorticoid receptor antagonist (MRA)."}
{"doc_id": "med:pmid:40540017", "sentence_id": "med:pmid:40540017:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Target doses of CDMT were achieved for 27% of males on ACEi/ARB/ARNI, 28% on BB, and 23% on MRA."}
{"doc_id": "med:pmid:40542996", "sentence_id": "med:pmid:40542996:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The highest incidence of HK was observed with the combination of angiotensin converting enzyme inhibitor (ACEi)/angiotensin ii receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitor (ARNi)+ mineralocorticoid receptor antagonists (MRAs) (24.4%), followed by the triple therapy ACEi/ARB/ARNi+ sodium glucose cotransporter-2 inhibitor (SGLT2i)+MRA (10.9%), and ACEi/ARB/ARNi + SGLT2i (2.2%)."}
{"doc_id": "med:pmid:40543460", "sentence_id": "med:pmid:40543460:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Quality metrics included antiplatelet and statin or proprotein convertase subtilisin/kexin type 9 inhibitor therapy for atherosclerotic cardiovascular disease prevention, blood pressure control, and GDMT for heart failure with reduced ejection fraction (HFrEF; specified beta blockers; ACEI, ARB, or ARNI; mineralocorticoid receptor antagonist)."}
{"doc_id": "med:pmid:40575771", "sentence_id": "med:pmid:40575771:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Currently, GDMT recommendations mainly include five types of drugs: diuretics, angiotensin receptor-neprilysin inhibitors (ARNIs), renin-angiotensin system inhibitors (ACEIs/ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i)."}
{"doc_id": "med:pmid:40660106", "sentence_id": "med:pmid:40660106:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Notably, 82% of patients were initiated on three or four drug classes concurrently at the start of treatment, most commonly including RAS inhibitors, MRAs, and beta-blockers, with a preference for ARNI over ACE inhibitors or ARBs."}
{"doc_id": "med:pmid:40679772", "sentence_id": "med:pmid:40679772:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among all patients in our study, 61.6% received either an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI); 57.0% were prescribed β-blockers; and 32.6% used a sodium-glucose cotransporter 2 inhibitor."}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:conclusion:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "initiation of ARNI after ADHF stabilization is more effective than ACEIs/ARBs for cardiovascular and renal outcomes, albeit with higher symptomatic hypotension risk."}
{"doc_id": "med:pmid:40689605", "sentence_id": "med:pmid:40689605:sec:introduction:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This meta-analysis evaluates ARNI versus angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) post-ADHF."}
{"doc_id": "med:pmid:40718065", "sentence_id": "med:pmid:40718065:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A high rate of ACEI/ARB/ARNI and BB use was observed."}
{"doc_id": "med:pmid:40718065", "sentence_id": "med:pmid:40718065:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among them, 82.7% (n=588) received angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or angiotensin receptor-neprilysin inhibitors (ARNIs); 82.3% (n=585) received beta-blockers (BBs); and 51.3% (n=365) were treated with mineralocorticoid receptor antagonists (MRAs)."}
{"doc_id": "med:pmid:40718065", "sentence_id": "med:pmid:40718065:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among patients with HFrEF, those receiving triple therapy (ACEI/ARB/ARNI + BB + MRA) had lower all-cause mortality compared to other groups (38.8%, log-rank p=0.014)."}
{"doc_id": "med:pmid:40727001", "sentence_id": "med:pmid:40727001:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "LASSO regression showed that the key predictors included age, BNP, New York Heart Association (NYHA) class, LVEF, PLR, MLR, AF history, and ACEI/ARB/ARNI usage."}
{"doc_id": "med:pmid:40755965", "sentence_id": "med:pmid:40755965:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis."}
{"doc_id": "med:pmid:40769236", "sentence_id": "med:pmid:40769236:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite robust evidence supporting their efficacy, the use of statins, ACEIs, and ARNIs remains suboptimal in Colombia."}
{"doc_id": "med:pmid:40769236", "sentence_id": "med:pmid:40769236:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Effective metabolic control and risk factor management, including evidence-based pharmacological therapies such as statins, ACE inhibitors (ACEIs), and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential for reducing adverse outcomes."}
{"doc_id": "med:pmid:40788620", "sentence_id": "med:pmid:40788620:sec:results:sent:3", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA)."}
{"doc_id": "med:pmid:40788620", "sentence_id": "med:pmid:40788620:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin-angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events."}
{"doc_id": "med:pmid:40791946", "sentence_id": "med:pmid:40791946:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "RAAS inhibitors including ACE inhibitors (18.1%), ARBs (25.2%), and ARNI (10.8%), were also frequently used."}
{"doc_id": "med:pmid:40835081", "sentence_id": "med:pmid:40835081:sec:abstract:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The use of guideline-directed medical therapy at discharge was suboptimal in both groups, but even lower in Chagas patients, particularly for beta-blockers (52% vs 64%, p = 0.02) and ACEi/ARB/ARNi (54% vs 68%, p = 0.01)."}
{"doc_id": "med:pmid:40839760", "sentence_id": "med:pmid:40839760:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Changes in LSS severity at 8 months were analysed using ordinal logistic regression models to estimate the effect of sacubitril/valsartan vs. enalapril or valsartan."}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator."}
{"doc_id": "med:pmid:40849246", "sentence_id": "med:pmid:40849246:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved."}
{"doc_id": "med:pmid:40869719", "sentence_id": "med:pmid:40869719:sec:abstract:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The review examines the efficacy of pharmacological therapies and their impact on readmission rates, highlighting key interventions such as diuretics, beta-blockers, ACE inhibitors, ARBs, ARNIs, SGLT2 inhibitors, and intravenous iron supplementation."}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI significantly reduced MEE compared with ACEI/ARB."}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "According to the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/ARNI, the 210 patients were divided into the ARNI group (107 cases, 51.0%) and the non-ARNI (ACEI/ARB) group (103 cases, 49.0%)."}
{"doc_id": "med:pmid:40873622", "sentence_id": "med:pmid:40873622:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI significantly reduced MEE after 1 year compared with the ACEI/ARB [(129.61 ± 40.81) kcal/min vs. (154.49 ± 47.58) kcal/min, <i>P</i> < 0.01]."}
{"doc_id": "med:pmid:40908036", "sentence_id": "med:pmid:40908036:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i)."}
{"doc_id": "med:pmid:40910162", "sentence_id": "med:pmid:40910162:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+β-blockers (BB)+sodium-glucose cotransporter 2 inhibitors (SGLT2i; MD, +5.3 [+0.4, +10.3]) was the most effective at improving quality of life followed by ARNi+BB+mineralocorticoid receptor antagonists (MRA)+SGLT2i (MD, +7.1 [-1.0 to +15.2]), ACE inhibitor+BB+MRA+SGLT2i (MD, +5.3 [-2.6, to +13.3]), and ACE inhibitor+BB+MRA+ivabradine (MD, +5.2 [-3.1 to +13.6]), which were not statistically significant."}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC)."}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid)."}
{"doc_id": "med:pmid:40916703", "sentence_id": "med:pmid:40916703:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial."}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "While most physicians (66%) knew the target doses for Sacubitril/Valsartan, 83% of them were unaware that the clinical benefit of sacubitril/valsartan at doses below 50% of the target compared to ACE inhibitors remains uncertain and is not well supported by current evidence."}
{"doc_id": "med:pmid:40981086", "sentence_id": "med:pmid:40981086:sec:abstract:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This finding raises questions about the clinical and economic value of initiating sacubitril/valsartan without subsequent dose optimization, especially given the uncertainty surrounding the efficacy of suboptimal dosing compared to ACE inhibitors."}
{"doc_id": "med:pmid:40993994", "sentence_id": "med:pmid:40993994:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the total population, from admission to discharge there was a increase in the use of angiotensin receptor-neprilysin inhibitor (ARNI) (17.1% to 34.3%), beta-blockers (69.4% to 92.4%), mineralocorticoid receptor antagonists (MRA) (44.0% to 82.1%) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) (30.8% to 79.9%), with a reduction in angiotensin-converting enzyme inhibitor (ACEI) use (all p < 0.05)."}
{"doc_id": "med:pmid:40993994", "sentence_id": "med:pmid:40993994:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Similar trends were observed across HF phenotypes, including HFrEF (increased use of ARNI, 26.3% to 55.1%, beta-blockers, 69.8% to 95.3%, MRA 49.5% to 89.0%, and SGLT2I 36.2% to 79.8%, and lower ACEI use, all p < 0.05)."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Angiotensin receptor-neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At the 6-week follow-up, in both subgroups, a significant improvement in the median LVEF values was achieved-from a median LVEF value of 30% (27.3; 38) to 37% (30; 43; <i>p</i> = 0.0008) in the ARNI subgroup and from a median LVEF value of 36% (33; 39) to 45% (42; 52; <i>p</i> < 0.0001) in the ACEI/ARB subgroup."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), <i>p</i> = 0.018]."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Similarly, the median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), <i>p</i> = 0.047]."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The study population was categorized into pts receiving ARNI and ACEI/ARB."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:introduction:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Finally, two groups (ARNI vs. ACEI/ARB) of 30 pts were obtained and analyzed at baseline and at a 6-week follow-up."}
{"doc_id": "med:pmid:41007826", "sentence_id": "med:pmid:41007826:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Impact of Sacubitril/Valsartan (ARNI) Compared with ACEI/ARB in Patients with Acute Myocardial Infarction on Post-Infarction Left Ventricular Systolic Dysfunction: A Retrospective Analysis."}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:conclusion:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Compared with ACEI/ARB, ARNI demonstrated enhanced preservation of cardiac function, attenuation of adverse ventricular remodeling, and maintenance of ventricular geometry following myocardial infarction."}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "To compare the effects of early angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy on left ventricular remodeling and heart failure progression in patients with acute anterior wall myocardial infarction."}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:methods:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were stratified by treatment into ARNI (n = 97) and ACEI/ARB (n = 71) groups."}
{"doc_id": "med:pmid:41016569", "sentence_id": "med:pmid:41016569:sec:results:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The ARNI group demonstrated significantly greater improvements in left ventricular end-diastolic diameter and relative wall thickness versus the ACEI/ARB group."}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:introduction:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) includes a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB)/angiotensin receptor neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor agonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i)."}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "GDMT use and dosing (none, <50%, ≥50 to <100%, 100% target dose) for beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i were assessed."}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Increasing age was linked to lower odds of ACEI/ARB/ARNI use, while higher systolic blood pressure (SBP) favored treatment."}
{"doc_id": "med:pmid:41049960", "sentence_id": "med:pmid:41049960:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among 236 eligible patients, only 16.5%, 10.2%, 31.4%, and 42.8% were receiving target doses of beta-blockers, ACEI/ARB/ARNI, MRA, and SGLT2i, respectively."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "LBBP combined with sacubitril/valsartan is more effective in treating elderly CHD with CHF than LBBP combined with enalapril."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "This study compares the efficacy and safety of LBBP combined with sacubitril/valsartan and LBBP combined with enalapril in treating elderly coronary heart disease (CHD) patients with chronic heart failure (CHF)."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Based on the postoperative treatment regimen, patients were divided into the LBBP & sacubitril/valsartan and the LBBP & enalapril groups."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Of them, 53 patients comprised the LBBP & sacubitril/valsartan group and 58 patients comprised the LBBP & enalapril group."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "After treatment, levels of LVEDd, LVEF, NT proBNP, sSt2 and MMP-9 in the LBBP & sacubitril/valsartan group were significantly improved compared to those in the LBBP & enalapril group (all P<0.05)."}
{"doc_id": "med:pmid:41070303", "sentence_id": "med:pmid:41070303:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure."}
{"doc_id": "med:pmid:41079061", "sentence_id": "med:pmid:41079061:sec:methods:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Medications analyzed included ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNI), and sodium-glucose co-transporter 2 inhibitors (SGLT2i)."}
{"doc_id": "med:pmid:41079061", "sentence_id": "med:pmid:41079061:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The most expensive medication regime for HF in Venezuela was ARNI-based GDMT with a median monthly cost of 393.81USD, followed by ARB-based GDMT and ACEi-based GDMT costing $100.88USD and $82.23USD respectively."}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:conclusion:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Early sacubitril/valsartan use was associated with reduced 1-year AF risk vs. ACEI/ARB in AMI complicated by MR, suggesting a potential role in this population; prospective trials are needed to confirm causality."}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:introduction:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Evidence remains limited regarding whether early administration of sacubitril/valsartan confers additional protection against new-onset AF in this high-risk population to traditional ACEI/ARB therapy."}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:methods:sent:4", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In this single-center retrospective cohort, 1,065 in-patients with AMI complicated by MR (June 2021-December 2023) were categorized by discharge prescription into the Sacubitril/Valsartan group (<i>n</i> = 427) or the ACEI/ARB group (<i>n</i> = 638).The primary endpoint was new-onset AF within 1 year."}
{"doc_id": "med:pmid:41079587", "sentence_id": "med:pmid:41079587:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Despite a higher baseline risk profile in the Sacubitril/Valsartan group, the 1-year cumulative incidence of AF was lower than in the ACEI/ARB group (CIF 10.8% vs. 17.9%; Gray's test <i>P</i> = 0.002)."}
{"doc_id": "med:pmid:41080832", "sentence_id": "med:pmid:41080832:sec:abstract:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Six secondary endpoints, including dose conversion from ACEi or ARB to ARNI therapy, were assessed."}
{"doc_id": "med:pmid:41084891", "sentence_id": "med:pmid:41084891:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In this subgroup, the use of angiotensin receptor‑neprilysin inhibitor (ARNI) / angiotensin‑converting enzyme inhibitor (ACEI) / angiotensin receptor blocker (ARB) increased from 81.5% of the patients at admission to 88.9% at discharge, of β‑blocker from 85% to 94.4%, of mineralocorticoid receptor antagonist (MRA) from 69.7% to 86.1%, and of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) from 59.2% to 83.6%."}
{"doc_id": "med:pmid:41084891", "sentence_id": "med:pmid:41084891:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI/ACEI/ARB therapy was optimized in 36.2% of the participants, while the rates of optimization were 24.7%, 27.2%, and 24.4% for β‑blockers, MRA, and SGLT2i, respectively."}
{"doc_id": "med:pmid:41084891", "sentence_id": "med:pmid:41084891:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 64 patients (22.3%) attained the 4‑pillar GDMT of SGLT2i, ARNI/ACEI/ARB, β‑blockers, and MRA at doses equal to or above 50% of the target dose."}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:conclusion:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among patients with HFrEF seen at the outpatient, there is good physician adherence to betablockers, ACEI/ARNI/ARBs, and diuretics."}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over three months of follow-up, improvement in the quality of care was demonstrated with ACEI/ARNI/ARBs (81.8% to 90.9%), MRA (68.7 to 81.2%), and SGLT2i (58% to 67.7%)."}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the 3<sup>rd</sup> month post-discharge, titration to optimal doses was achieved in only 26.4%, 15%, and 6.25% for those on beta-blockers, ACEI/ARNI/ARB, and MRA, respectively."}
{"doc_id": "med:pmid:41126807", "sentence_id": "med:pmid:41126807:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, adherence to prescription of beta-blockers (94.8%), ACEI/ARNI/ARBs (88.5%), and diuretics (100%) were high."}
{"doc_id": "med:pmid:41136931", "sentence_id": "med:pmid:41136931:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Target dose attainment varied by drug class: 78% for beta-blockers, 63% for ACEI/ARB/ARNI, 96% for MRAs, and 100% for ivabradine."}
{"doc_id": "med:pmid:41151613", "sentence_id": "med:pmid:41151613:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Since 2021, evidence‑based management of heart failure with reduced ejection fraction (HFrEF) has centred on four pharmacological \"pillars\": β‑blockers, sacubitril/valsartan (or an ACE inhibitor), mineralocorticoid‑receptor antagonists, and sodium-glucose co‑transporter‑2 (SGLT‑2) inhibitors."}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sensitivity analyses excluding one study showed significant improvements in ACEi/ARB/ARNI prescriptions (OR: 1.36, [95% CI: 1.10, 1.69])."}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Subgroup analyses showed significant improvements in ACEi/ARB/ARNI (OR:1.35, [95% CI: 1.03, 1.77)]) and beta-blockers (OR:1.48, [95% CI: 1.31, 1.68)]) prescriptions along with reduced total mortality (OR: 0.86, [95% CI: 0.76, 0.98]) in hospitals."}
{"doc_id": "med:pmid:41249923", "sentence_id": "med:pmid:41249923:sec:results:sent:16", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In another subgroup analyses, shorter follow-up periods were associated with improvement in ACEi/ARB/ARNI (OR:1.38, [95% CI: 1.08, 1.77]), beta-blockers (OR: 1.45, [95% CI: 1.28, 1.61]) prescriptions and total mortality (OR: 0.86, [95% CI: 0.75, 0.99])."}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:14", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "No significant between-group differences were observed in drug utilization rate of β-blockers, ACEI/ARB/ARNI, or sodium-glucose cotransporter 2 inhibitors during follow-up (all <i>P</i>>0.05), while mineralocorticoid receptor antagonists use showed a declining trend in both groups."}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:15", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Although the core hospital-treated group had higher target dose achievement rates for β-blockers (65.4% vs. 49.3%, <i>P</i>=0.042) and ACEI/ARB/ARNI (79.8% vs. 65.8%, <i>P</i>=0.046) than the two-way referral group, multivariate logistic regression indicated that the two-way referral model was not a negative predictor for these outcomes (all <i>P</i>>0.05)."}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients underwent followed-up, with primary endpoints including follow-up rate, drug (β-blockers, angiotension converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists) utilization rate and target dose achievement rate."}
{"doc_id": "med:pmid:41287294", "sentence_id": "med:pmid:41287294:sec:abstract:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Multivariate logistic regression was used to identify factors influencing target dose achievement rate for β-blockers and ACEI/ARB/ARNI therapies in CHF patients."}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ATTRwt-CA patients on beta-blockers or ACEi/ARB/ARNI at diagnosis did not have a shorter survival."}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:conclusion:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Beta-blockers were discontinued less often than were ACEi/ARB/ARNI."}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "At diagnosis, 60% of patients were on beta-blockers, 58% on ACEi/ARB/ARNI, and 35% on MRA."}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients on beta-blockers had more often NYHA class III/IV, a greater burden of comorbidities, and lower LVEF, and those on ACEi/ARB/ARNI had more comorbidities."}
{"doc_id": "med:pmid:41296625", "sentence_id": "med:pmid:41296625:sec:results:sent:7", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Nonetheless, the survival of patients on beta-blockers or ACEi/ARB/ARNI was not significantly shorter over a 2.5-year follow-up (1.6-3.8) (P = 0.577 and P = 0.977, respectively), and patients on both drugs did not have a worse outcome than those not receiving any neurohormonal drug (P = 0.575)."}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "ARNI/ACEI/ARB therapy was optimized in 48.4% of the subjects, with optimization rates of 37.9%, 40.2%, and 44.1% for beta-blockers, MRAs, and SGLT2is, respectively."}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "However, only 38 (22.0%) patients reached the level of treatment corresponding to \"SGLT2i and ARNI/ACEI/ARB and betablocker and MRA in doses ≥ 50%\"."}
{"doc_id": "med:pmid:41303015", "sentence_id": "med:pmid:41303015:sec:introduction:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the analysis for the whole group (regardless of ejection fraction [EF]), ARNI (angiotensin receptor-neprilysin inhibitor)/ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin receptor blocker) use increased from 63.3% of the subjects at admission to 81.3% at discharge, beta-blocker use increased from 70.6% to 92.6%, MRA (mineralocorticoid receptor antagonist) use increased from 43.1% to 75.8%, and SGLT2i (sodium-glucose co-transporter 2 inhibitor) use increased from 30.1% to 75.0%."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:methods:sent:5", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or enalapril (target dose, 10 mg twice daily), in addition to standard therapy."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "A total of 102 patients (22.1% [7.7% wins]) in the sacubitril/valsartan group and 111 (24.1% [6.9% wins]) in the enalapril group experienced a first hospitalization for HF."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Patients in the sacubitril/valsartan group had a median (IQR) decrease in NT-proBNP of 30.6% (-54.3% to -0.9%) at 12 weeks, leading to 22.5% wins, while those in the enalapril group had a 5.5% (-31.9% to 37.5%) decrease (7.2% wins)."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:12", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "The resulting stratified win ratio was 1.52 (95% CI, 1.28-1.82; P < .001) for sacubitril/valsartan compared with enalapril."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:13", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "<h4>Conclusions and relevance</h4> In patients with HF with reduced ejection fraction due to Chagas disease, there was no significant difference in clinical outcomes between sacubitril/valsartan and enalapril, but there was a greater reduction in NT-proBNP at 12 weeks in patients in the sacubitril/valsartan group."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Overall, 462 participants were randomized to receive sacubitril/valsartan and 460 to receive enalapril (mean [SD] age, 64.2 [10.8] years; 387 [42.0%] were female)."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:results:sent:9", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Over a median (IQR) follow-up of 25.2 (18.4-33.2) months, cardiovascular death occurred in 110 patients (23.8% [18.3% wins in the hierarchical comparison]) in the sacubitril/valsartan group and 117 patients (25.4% [17.5% wins]) in the enalapril group."}
{"doc_id": "med:pmid:41335448", "sentence_id": "med:pmid:41335448:sec:title:sent:0", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial."}
{"doc_id": "med:pmid:41377094", "sentence_id": "med:pmid:41377094:sec:results:sent:8", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In multivariable regression analysis, older age was the only independent socio-demographic predictor of under-prescription both overall and for ACEi/ARB/ARNI (OR0.70; 95% CI 0.55-0.89), beta-blockers (OR0.59; 95% CI 0.41-0.84) and SGLT2i (OR0.66, 95% CI 0.47-0.93), while also associated with a loop diuretics use (OR1.56; 95% CI 1.13-2.17)."}
{"doc_id": "med:pmid:41379379", "sentence_id": "med:pmid:41379379:sec:abstract:sent:1", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Chronic heart failure with reduced ejection fraction (HFrEF) is a progressive syndrome associated with substantial residual morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT) - angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) [1]."}
{"doc_id": "med:pmid:41408894", "sentence_id": "med:pmid:41408894:sec:results:sent:10", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i."}
{"doc_id": "med:pmid:41408894", "sentence_id": "med:pmid:41408894:sec:results:sent:11", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i."}
{"doc_id": "med:pmid:41408894", "sentence_id": "med:pmid:41408894:sec:results:sent:6", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor-neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium-glucose co-transporter 2 inhibitors (SGLT2i)."}
{"doc_id": "med:pmid:41455057", "sentence_id": "med:pmid:41455057:sec:abstract:sent:2", "product_a": "enalapril", "product_b": "sacubitril_valsartan", "sentence_text": "In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation."}
